Recce Pharmaceuticals Ltd

[Available On-Demand] ・ Click video to start playback; Join chat Q&A below video
Search General Info
Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering a New Class of Broad-Spectrum Synthetic Antibiotics. Designed to address the global health threat of antibiotic resistant superbugs, RECCE antibiotics continues to work, even with repeated use.

Lead candidate RECCE® 327 has been developed for the treatment of sepsis derived from E. coli and S. aureus bacteria as well as multi-drug resistant bacterial infections. The FDA has awarded RECCE® 327 QIDP designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.
Ticker:
RCE
Exchange:
ASX
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2008
Main Therapeutic Focus:
Lead Product in Development:
RECCE 327
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
Executive Director
Recce Pharmaceuticals Ltd